An interventional study of Active iTBS and Tablet-based upper limb training in Chronic Stroke Patient, Motor Impairment and Neurorehabilitation, sponsored by School of Health Sciences Geneva. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by School of Health Sciences Geneva · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.
Among the 216 studies in Stroke with a site in Switzerland, this one is the 91st largest by planned enrollment of the 147 interventional ones that give a count, is one of 12 that started in 2025, is one of 95 with no phase, reaches primary completion later than 19 of the 59 other live ones, and was the 203rd registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Switzerland, Belgium, Germany and 3 more countries
Ages 18+
Ecole Polytechnique Fédérale de Lausanne · Sites in Switzerland
Ages 18–70
Centre Hospitalier Universitaire Vaudois · Sites in Switzerland
Ages 18–85
School of Health Sciences Geneva · Sites in Switzerland
Ages 18+
Sigmund Freud PrivatUniversitat · Sites in Switzerland, Austria, Germany
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
216 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 37 · Phase 4 7
First in 1998; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is close to the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 79 across the 147 interventional studies, 200 across the 69 observational. Of the 134 that completed or were terminated, 19 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 216 have an industry lead sponsor. The 10 most frequent:
School of Health Sciences Geneva is the lead sponsor of 22 studies on the registry; 5 are open to participants now.
School of Health Sciences Geneva has 4 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
10 of the studies in Stroke with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02756091Insel Gruppe AG, University Hospital BernInternational Intracranial Dissection Study | 2026-11-30 |
| NCT06466772University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT07739134ETH ZurichMultimodal Tracking of Therapy Activity and Effort During Rehabilitation | 2026-12-30 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT07444151School of Health Sciences GenevaPost-Stroke Fatigue Perception Study (ReFast) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 216 studies in Stroke with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Stroke is one of the leading causes of long-term disability worldwide. Many individuals who survive a stroke continue to experience weakness and reduced control of one arm, even months or years after the event. These motor impairments significantly affect independence, daily activities, and quality of life. Despite rehabilitation efforts, recovery of upper limb function remains incomplete for many patients.
Motor recovery after stroke depends on the brain's ability to reorganize itself, a process known as neuroplasticity. Recent research suggests that motor learning and brain recovery are influenced not only by activity in the primary motor cortex (M1), but also by its functional connectivity with other brain regions, particularly the parietal cortex (PC). Strengthening communication between these regions may enhance motor recovery.
This study aims to investigate a novel, non-invasive brain stimulation approach called intermittent theta-burst stimulation (iTBS). Unlike traditional stimulation methods that target a single brain region, this study uses a multifocal stimulation protocol targeting both the primary motor cortex and the parietal cortex. The stimulation is combined with structured motor training using an interactive tablet-based rehabilitation device (REAtouch®Lite 2), designed to improve arm movement through goal-directed reaching tasks.
The study is a single-center, randomized, sham-controlled, triple-blind clinical trial with parallel groups. Thirty-six individuals with chronic stroke-related upper limb impairment will be randomly assigned to receive either active multifocal iTBS or sham (placebo) stimulation. Both groups will complete identical motor training sessions. In addition, ten healthy participants will complete the same motor training protocol (without brain stimulation) to provide reference data.
Participants will attend six visits over approximately 10 days. Assessments will include motor performance tests using the interactive tablet, a standardized clinical motor scale (Fugl-Meyer Assessment for Upper Extremity), and resting-state electroencephalography (EEG) to measure brain connectivity changes.
The primary outcome is improvement in motor performance between baseline and one week after the intervention. Secondary outcomes include short-term motor improvements, retention of learning, changes in movement quality, and changes in brain functional connectivity.
This study seeks to determine whether combining multifocal brain stimulation with targeted motor training can enhance motor learning and promote better recovery of arm function after stroke. If effective, this approach could contribute to the development of more precise, network-based neurorehabilitation strategies.
Stroke is a leading cause of long-term motor disability, with persistent upper limb impairment affecting a large proportion of individuals in the chronic phase. Despite advances in rehabilitation, recovery of arm function remains limited for many patients. Motor recovery after stroke depends on neuroplastic reorganization within distributed brain networks. While most neuromodulation studies have focused on stimulating the primary motor cortex (M1) alone, growing evidence indicates that motor learning relies on coordinated interactions between multiple cortical regions, particularly the functional connectivity between the parietal cortex (PC) and M1.
Resting-state functional connectivity between parietal and motor areas has been identified as a neurophysiological marker associated with motor performance and recovery potential. Enhancing this network-level connectivity may therefore represent a promising strategy to improve motor learning and functional outcomes after stroke.
The INSPIRE project investigates a novel multifocal intermittent theta-burst stimulation (iTBS) paradigm targeting both M1 and PC. Intermittent theta-burst stimulation is a patterned form of repetitive transcranial magnetic stimulation (rTMS) capable of inducing lasting modulation of cortical excitability. In contrast to conventional monofocal approaches, this study applies neuronavigated iTBS sequentially over M1 and the superior parietal lobule within the affected hemisphere, with the objective of modulating network-level interactions rather than isolated cortical excitability.
The stimulation protocol is combined with structured motor training delivered through a tablet-based interactive device (REAtouch®Lite 2). This system implements a standardized two-dimensional reaching task that allows precise quantification of motor performance and spatio-temporal movement parameters. The combination of neuromodulation and task-specific training is designed to engage Hebbian plasticity mechanisms, whereby stimulation-induced network modulation may facilitate motor learning processes during training.
This study is designed as a single-center, randomized, sham-controlled, triple-blind, parallel-group clinical trial. Thirty-six individuals in the chronic phase after a first stroke (≥6 months) with moderate upper limb impairment will be randomized in a 1:1 ratio to receive either active multifocal iTBS or sham stimulation. Both groups will undergo identical motor training sessions. A group of ten age- and sex-matched healthy participants will complete the same motor training protocol without brain stimulation to provide normative reference data for behavioral and neurophysiological measures.
The intervention consists of two consecutive days of stimulation combined with motor training. Each session includes neuronavigated iTBS delivered over M1 and PC (600 pulses per target at 70% resting motor threshold), followed by 45 minutes of structured motor training. Sham stimulation reproduces auditory and sensory aspects of active stimulation without inducing a cortical electric field.
Motor performance is assessed using a composite motor performance index derived from reaching accuracy and movement time during a standardized visuo-motor task. Secondary behavioral measures include short-term learning indices, offline consolidation effects, detailed spatio-temporal movement parameters, and clinical motor impairment assessed with the Fugl-Meyer Assessment for Upper Extremity (FMA-UE).
Neurophysiological outcomes include resting-state electroencephalography (EEG) recorded before and after the intervention. Functional connectivity between parietal and motor regions is quantified using frequency-specific coherence measures and graph-theoretical metrics. These analyses aim to determine whether multifocal iTBS enhances cortico-cortical connectivity and whether changes in connectivity are associated with behavioral improvements.
The primary hypothesis is that multifocal iTBS combined with motor training will lead to greater improvements in motor performance compared with sham stimulation. Secondary hypotheses include enhanced short-term motor learning, improved retention of learned motor skills, and increased parieto-motor functional connectivity in the active stimulation group.
This project integrates behavioral, clinical, and neurophysiological measures to evaluate a network-based neuromodulation approach in chronic stroke rehabilitation. By targeting distributed cortical interactions rather than a single cortical region, the study aims to advance precision neurorehabilitation strategies grounded in contemporary models of motor learning and brain network plasticity.
If successful, this intervention paradigm could inform future rehabilitation protocols and support the development of individualized, connectivity-driven therapeutic approaches for stroke recovery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Stroke Participants:
For Healthy Participants:
Exclusion Criteria:
For Stroke Participants:
For Healthy Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
active iTBS stimulation prior to tablet-based motor training
Device: Active iTBS · Device: Tablet-based upper limb training
sham iTBS stimulation prior to tablet-based motor training
Device: Tablet-based upper limb training · Device: Sham iTBS
no brain stimulation; tablet-based motor training only
Device: Tablet-based upper limb training
Standard 600-pulse intermittent theta burst stimulation (iTBS) can increase corticomotor excitability. The iTBS will be delivered with an intensity of 70% of the individual resting motor threshold (RMT) over the ipsilesional primary motor cortex (M1) and superior parietal lobule using a Magstim Rapid2 stimulator equipped with a figure-of-eight coil. Stimulation will follow the standard iTBS pattern consisting of bursts of 3 pulses at 50 Hz repeated at 5 Hz.
REAtouch® Lite 2 interactive rehabilitation device will be used for upper limb motor training. REAtouch® Lite 2 is a touchscreen-based, task-oriented rehabilitation device designed to train upper limb movements through interactive exercises. The device targets (1) goal-directed reaching movements, (2) hand transport toward visual targets, (3) grasp and release coordination in a two-dimensional workspace, and (4) movement accuracy and speed. Training is supported by customizable visual feedback and task-specific interactive exercises integrated into the device.
Sham intermittent theta burst stimulation (iTBS) mimics the auditory and somatosensory characteristics of active stimulation without inducing a biologically effective cortical electric field. Sham stimulation will be delivered over the ipsilesional primary motor cortex (M1) and superior parietal lobule using a placebo coil identical in appearance, sound, and positioning to the active coil. Stimulation procedures, session duration, neuronavigation, and device setup are identical to the active iTBS condition to ensure participant and assessor blinding.
Change in Global Motor Performance Index (Baseline to Day 10)
The primary outcome is the change in the Global Motor Performance Index score between baseline (Day 0) and post-intervention follow-up (Day 10). The Global Motor Performance Index is a composite performance score derived from a standardized two-dimensional reaching task performed using the REAtouch® Lite 2 interactive rehabilitation device. The index integrates movement accuracy (number of errors) and movement time into a single continuous score. The score ranges from -100 to +100, with lower (more negative) values indicating better motor performance and improvement over time, and higher values indicating worse performance.
Time frame: Baseline (Day 0) to Day 10
Change in Short-Term Motor Performance Index (Baseline to Day 3)
This outcome evaluates short-term motor learning effects by measuring the change in the Short-Term Motor Performance Index score between Baseline (Day 0) and immediate post-intervention (Day 3). The Short-Term Motor Performance Index is a composite continuous score derived from a standardized two-dimensional reaching task performed using the REAtouch® Lite 2 interactive rehabilitation device. The index integrates movement accuracy (number of errors) and movement time into a single performance metric. The score ranges from -100 (best motor performance) to +100 (worst motor performance). Lower (more negative) scores indicate better motor performance, and a decrease in the score over time reflects motor improvement.
Time frame: Baseline (Day 0) to Day 3
Offline Motor Consolidation Index (Day 3 to Day 10)
This outcome assesses motor memory consolidation by measuring the change in the Offline Motor Consolidation Index score between immediate post-intervention (Day 3) and follow-up (Day 10). The Offline Motor Consolidation Index is a continuous composite score derived from the same standardized two-dimensional reaching task performed using the REAtouch® Lite 2 interactive rehabilitation device. The index reflects performance retention or change after completion of the stimulation and training sessions. The score ranges from -100 (best motor performance) to +100 (worst motor performance). Lower (more negative) scores indicate better motor performance. A decrease in the score between Day 3 and Day 10 reflects performance improvement, whereas stable scores indicate retention and an increase indicates performance deterioration.
Time frame: Day 3 to Day 10
Change in Upper Limb Motor Impairment (Fugl-Meyer Assessment - Upper Extremity)
Upper limb motor impairment will be assessed using the Fugl-Meyer Assessment - Upper Extremity (FMA-UE), a validated clinical scale measuring motor function of the upper limb after stroke. The FMA-UE total score ranges from 0 to 66, where 0 indicates severe motor impairment and 66 indicates normal motor function. Higher scores represent better motor function. Change in FMA-UE scores over time will be analyzed to evaluate clinical motor recovery.
Time frame: Baseline (Day 0), Day 3, and Day 10
Change in Mean Number of Reaching Errors
The mean number of reaching errors will be measured during a standardized two-dimensional reaching task performed using the REAtouch® Lite 2 interactive rehabilitation device. An error is defined as failure to reach or stabilize within the predefined target area during a trial. The outcome is a continuous variable representing the average number of errors per session. The minimum possible value is 0 (no errors), with no predefined upper limit. Higher values indicate worse motor performance. Changes in the mean number of errors over time will be analyzed.
Time frame: Baseline (Day 0), Day 3, and Day 10
Change in Mean Movement Speed (cm/s)
Mean movement speed will be measured during a standardized two-dimensional reaching task performed using the REAtouch® Lite 2 interactive rehabilitation device. Movement speed (cm/s) is calculated as the displacement divided by the time between movement initiation (defined as \>5 mm displacement from the starting position) and movement stabilization within the target area. This is a continuous variable with a minimum possible value of 0 cm/s and no predefined upper limit. Higher values indicate faster movement performance. Changes in mean movement speed over time will be analyzed.
Time frame: Baseline (Day 0), Day 3, and Day 10
Change in Mean Movement Smoothness (cm/s³)
Mean movement smoothness will be measured during a standardized two-dimensional reaching task performed using the REAtouch® Lite 2 interactive rehabilitation device. Movement smoothness is quantified using a jerk-based metric (third derivative of position with respect to time), expressed in centimeters per second cubed (cm/s³). The metric reflects the magnitude of trajectory corrections during movement execution. This is a continuous variable with a minimum possible value of 0 cm/s³ and no predefined upper limit. Lower values indicate smoother movements and better motor control, whereas higher values indicate greater movement irregularity. Changes in mean movement smoothness over time will be analyzed.
Time frame: Baseline (Day 0), Day 3, and Day 10
Change in Mean Maximum Lateral Deviation (cm)
Mean maximum lateral deviation will be measured during a standardized two-dimensional reaching task performed using the REAtouch® Lite 2 interactive rehabilitation device. Maximum lateral deviation (cm) is defined as the greatest perpendicular distance between the participant's actual movement trajectory and the optimal straight-line trajectory from the start position to the target. This is a continuous variable with a minimum possible value of 0 cm (perfectly straight trajectory) and no predefined upper limit. Lower values indicate better trajectory control and movement accuracy, whereas higher values indicate greater deviation from the optimal path. Changes in mean maximum lateral deviation over time will be analyzed.
Time frame: Baseline (Day 0), Day 3, and Day 10
Change in Mean Directional Error at 100 ms (degrees)
Mean directional error at 100 milliseconds will be measured during a standardized two-dimensional reaching task performed using the REAtouch® Lite 2 interactive rehabilitation device. Directional error (degrees) is defined as the angular deviation between the initial movement direction and the straight-line direction to the target, calculated 100 milliseconds after movement onset. Movement onset is defined as displacement exceeding 5 mm from the starting position. This is a continuous variable expressed in degrees, with a minimum possible value of 0° (perfect alignment with the target direction) and no predefined upper limit. Lower values indicate greater motor planning accuracy, whereas higher values indicate greater deviation from the intended direction. Changes in mean directional error over time will be analyzed.
Time frame: Baseline (Day 0), Day 3, and Day 10
Change in Mean Reaction Time (seconds)
Mean reaction time will be measured during a standardized two-dimensional reaching task performed using the REAtouch® Lite 2 interactive rehabilitation device. Reaction time (seconds) is defined as the time elapsed between target appearance and movement initiation in the correct direction, defined as an initial movement trajectory within ≤15° of the straight-line direction to the target. Movement initiation is defined as displacement exceeding 5 mm from the starting position. This is a continuous variable expressed in seconds, with a minimum possible value of 0 seconds and no predefined upper limit. Lower values indicate faster response initiation and better motor preparation, whereas higher values indicate slower response initiation. Changes in mean reaction time over time will be analyzed.
Time frame: Baseline (Day 0), Day 3, and Day 10
Change in Parieto-Motor Functional Connectivity Measured by Resting-State EEG
Resting-state electroencephalography (EEG) will be used to assess functional connectivity between parietal and motor cortical regions. Functional connectivity will be quantified using frequency-specific coherence values and graph-theoretical network metrics derived from EEG signals. Coherence values range from 0 to 1, with higher values indicating stronger functional connectivity between cortical regions. Graph-based metrics (e.g., global efficiency, clustering coefficient) are continuous measures without fixed theoretical minimum or maximum values; higher values indicate greater network integration or segregation depending on the specific metric analyzed. Change in these connectivity measures between Baseline (Day 0) and Day 3 will be analyzed to evaluate neurophysiological effects of stimulation.
Time frame: Baseline (Day 0) and Day 3
Upper Limb Active Duration (minutes)
Upper limb activity during motor training sessions will be quantified using a wrist-worn ActiGraph® device. Active duration (minutes) is defined as the total time during each training session in which wrist acceleration exceeds the predefined activity threshold. This is a continuous variable expressed in minutes, with a minimum possible value of 0 minutes and a maximum corresponding to the total session duration. Higher values indicate greater active training time. These values will be used to verify equivalence of training dose across study groups.
Time frame: During Intervention Sessions (Day 1 and Day 2)
Mean Movement Intensity (vector magnitude counts)
Upper limb movement intensity during motor training sessions will be quantified using a wrist-worn ActiGraph® device. Mean movement intensity is calculated as the average vector magnitude of triaxial acceleration signals recorded during each training session. This is a continuous variable expressed in activity counts (vector magnitude units) with no predefined theoretical maximum. Higher values indicate greater movement intensity. These values will be used to verify equivalence of training intensity across study groups.
Time frame: During Intervention Sessions (Day 1 and Day 2)
Percentage of Active Time (%)
Upper limb activity during motor training sessions will be quantified using a wrist-worn ActiGraph® device. Percentage of active time (%) is defined as the proportion of total session time during which wrist acceleration exceeds the predefined activity threshold. This is a continuous variable expressed as a percentage ranging from 0% to 100%. Higher values indicate greater proportion of active training time. These values will be used to verify equivalence of training exposure across study groups.
Time frame: During Intervention Sessions (Day 1 and Day 2)
Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in publications will be shared. This includes behavioral motor performance data, spatio-temporal movement parameters, Fugl-Meyer Assessment scores (for stroke participants), resting-state EEG-derived functional connectivity measures, and relevant demographic and clinical variables necessary to reproduce the analyses. All shared datasets will be fully anonymized and stripped of direct and indirect identifiers in accordance with applicable data protection regulations. Data will be made available to qualified researchers upon reasonable request and after approval of a methodologically sound research proposal. A data-sharing agreement will be required to ensure appropriate use of the data.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Individual participant data (IPD) and supporting information will be available beginning 6 months after publication of the primary results and will remain available for a period of 5 years following publication.
Access criteria: De-identified individual participant data (IPD) and supporting documents (study protocol, statistical analysis plan, and analytic code) will be available to qualified researchers whose proposed use of the data has been approved by the study investigators. Access will be granted upon submission of a methodologically sound research proposal that is aligned with the scientific objectives of the original study. Requests must include a research plan, statistical analysis outline, and evidence of institutional affiliation. Data will be shared under a formal data-sharing agreement to ensure appropriate use, confidentiality, and compliance with applicable data protection regulations. Data will be transferred securely via encrypted electronic files or through a controlled-access institutional data repository.
Started Sep 2025 (actual). Primary completion is estimated for Aug 2026, 11 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 11 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
School of Health Sciences Geneva